Summary of Conference Call Notes Industry or Company Involved - Focus on the convertible bond market and its relation to various industries including pharmaceuticals, electronics, photovoltaic, and semiconductor sectors [1][2][3][4][6][7][10][11][12][13][17][18][19][20][21][22][24][25][26] Core Points and Arguments - **Tariff Uncertainty**: Increased uncertainty regarding tariffs is affecting the pharmaceutical and electronics industries, necessitating companies to monitor their exposure to the U.S. market and downstream demand [1][3][4] - **Market Sentiment**: Current equity market sentiment is optimistic, but convertible bond strategies should focus on defensive measures due to the risk of downward price fluctuations as valuations are no longer at historical lows [1][4][5] - **Photovoltaic Bonds**: Photovoltaic convertible bonds are facing heightened credit risk concerns, with market confidence in these bonds decreasing. Caution is advised regarding high-yield photovoltaic convertible bonds [1][6] - **Investment Strategies**: Recommended strategies include focusing on stable performance companies with policy or technological drivers, and emphasizing low-priced defensive positions [1][7][9][20] - **Key Recommendations**: Suggested sectors for investment include self-sufficiency (pharmaceuticals, semiconductors) and domestic demand recovery (consumption, infrastructure, real estate) [1][7][9][10] - **High Dividend Stocks**: Attention should be given to high dividend or income-oriented stocks, particularly new convertible bonds and bank stocks, as funds may shift from high-volatility assets to more stable investments [1][9][10] Other Important but Possibly Overlooked Content - **Sector-Specific Impacts**: - The electronics and textile industries have a high proportion of overseas business, making them more susceptible to tariff impacts [2][11][12] - The semiconductor industry is benefiting from domestic substitution logic, despite some exposure to tariffs [13] - Automotive parts suppliers have established overseas production to mitigate tariff impacts, maintaining competitive strength [14] - The mechanical industry has reduced its exposure to the U.S. market, thus facing less tariff impact [15][16] - **Performance Insights**: Companies with significant profit growth in Q1 2025 include a range of sectors, indicating potential investment opportunities [21][22][24][25][26] - **Market Trends**: The first quarter of 2025 is expected to show strong performance in sectors like non-ferrous metals, midstream manufacturing, and AI computing, which are worth monitoring for convertible bond investments [26]

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown mixed performance, with a recent decline of 1.18% and a year-to-date drop of 3.06% [1][2]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services closed at 13,112.97 points with a trading volume of 12.648 billion [1]. - Over the past month, the index has decreased by 8.47%, while it has increased by 1.50% over the last three months [1]. - The index was established on December 31, 2004, with a base point of 1,000.0 [1]. Group 2: Index Composition - The top ten weighted companies in the index include Mindray Medical (9.22%), Aier Eye Hospital (8.37%), and United Imaging Healthcare (7.65%) [1]. - The index is composed entirely of companies from the healthcare sector, with a market share distribution of 60.07% from the Shenzhen Stock Exchange and 39.93% from the Shanghai Stock Exchange [1][2]. Group 3: Fund Tracking - Several public funds track the index, including Southern CSI Healthcare Equipment and Services Link A, Tianhong CSI Healthcare Equipment and Services ETF, and others [2].

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a mixed performance, with a recent increase but a decline over the past month and year-to-date [1] Group 1: Index Performance - The CSI Healthcare Equipment and Services Index rose by 0.32% to 13,285.51 points, with a trading volume of 13.924 billion yuan [1] - Over the past month, the index has decreased by 8.06%, while it has increased by 4.05% over the last three months and has declined by 3.25% year-to-date [1] Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities [1] - The top ten weighted companies in the index include Mindray Medical (9.16%), Aier Eye Hospital (8.31%), and United Imaging Healthcare (7.43%) [1] - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (60.27%) and the Shanghai Stock Exchange (39.73%) [1] Group 3: Sample Adjustment and Fund Tracking - The index samples are adjusted biannually, with adjustments occurring on the second Friday of June and December [2] - Public funds tracking the healthcare index include several funds from Southern Asset Management and Tianhong Asset Management [2]

证券研究报告 | 医药生物 | 2025年4月12日 www.hczq.com 华创医药投资观点&研究专题周周谈·第121期 海外CXO 2024财报总结 本周周专题联系人：万梦蝶 | 华创医药团队： | | | --- | --- | | 首席分析师 郑辰 | 执业编号：S0360520110002 邮箱：zhengchen@hcyjs.com | | 联席首席分析师 刘浩 | 执业编号: S0360520120002 邮箱: liuhao@hcyjs.com | | 医疗器械组组长 李婵娟 | 执业编号：S0360520110004 邮箱：lichanjuan@hcyjs.com | | 中药和流通组组长 高初蕾 | 执业编号：S0360524070002 邮箱：gaochulei@hcyjs.com | | 分析师 万梦蝶 | 执业编号: S0360523080008 邮箱: wanmengdie@hcyjs.com | | 分析师 王宏雨 | 执业编号：S0360523080006 邮箱：wanghongyu@hcyjs.com | | 分析师 朱珂琛 | 执业编号：S0360524070007 邮箱 ...

Group 1 - The core index of the China Securities Internet Medical Theme Index (CS Internet Medical, 930720) opened lower but rose, closing at 2514.46 points with a trading volume of 6.017 billion yuan [1] - Over the past month, the CS Internet Medical Theme Index has decreased by 12.73%, increased by 15.90% over the past three months, and has risen by 5.70% year-to-date [1] - The index reflects the overall performance of representative companies providing hardware, software, or services for medical informationization and intelligence [1] Group 2 - The top ten weighted companies in the CS Internet Medical Theme Index are: Yifeng Pharmacy (6.65%), Daclin (6.44%), Laobaixing (6.21%), Wandong Medical (5.53%), Haier Biomedical (5.48%), Jiuzhoutong (5.44%), Yixintang (5.37%), Aier Eye Hospital (5.33%), Yuyue Medical (5.28%), and Lepu Medical (5.17%) [1] - The market share of the CS Internet Medical Theme Index holdings is 51.03% from the Shenzhen Stock Exchange and 48.97% from the Shanghai Stock Exchange [1] - The industry composition of the index holdings shows that 70.41% is in pharmaceuticals and healthcare, 25.78% in information technology, and 3.81% in communication services [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day after the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] Group 4 - Public funds tracking the CS Internet Medical Index include: Huatai-PineBridge China Securities Internet Medical A and Huatai-PineBridge China Securities Internet Medical C [3]

Core Insights - The integration of AI in healthcare is transforming the industry, with significant advancements showcased at the 91st China International Medical Equipment Fair (CMEF) [2][4][10] - The Chinese government is actively supporting the innovation and development of medical devices through policy reforms and financial incentives, including a special bond of 148 billion yuan [2][15] - Domestic companies are making strides in high-end medical equipment, with products that enhance precision and accessibility in healthcare [10][15][22] Group 1: AI and Medical Technology - The AI-driven medical models, such as Mindray's "Qiyuan" critical care model, can integrate patient data and provide treatment suggestions within five seconds, already implemented in several top-tier hospitals [4][10] - Haier Biomedical has launched an AI strategy with its "Kuidou" sample library model, focusing on intelligent management of biological samples [4][6] - The emergence of AI-powered solutions in blood sugar management, remote emergency care, and imaging diagnostics is pushing the medical field from "assistance" to "autonomy" [4][10] Group 2: Innovations in Medical Devices - The introduction of the "Newton 3D" intraoperative CT and surgical robot by GeRui Technology showcases advancements in precision surgery, offering real-time 3D imaging and navigation for complex procedures [13] - The ZAP-X radiation surgery robot, featuring a unique self-shielding design, is aimed at improving the safety and precision of radiation therapy for brain and head-neck tumors [15] - The launch of innovative non-invasive respiratory devices, such as the SyncFree algorithm-based respiratory machine by Yuyue Medical, highlights the shift towards home healthcare solutions [20] Group 3: Market Trends and Consumer Needs - The demand for home healthcare solutions is rising, particularly for chronic conditions like COPD and OSA, with projections indicating significant increases in patient numbers by 2025 [16][18] - The domestic hearing aid market is experiencing a transformation, with local products now competing with foreign brands due to advancements in technology and affordability [20] - The overall vitality of the domestic medical device industry is evident, as it continues to evolve towards high-quality development and innovation [22]

Group 1 - The core viewpoint of the news is that the CSI Medical Index has shown fluctuations, with a recent increase of 1.73% despite a decline of 11.00% over the past month [1] - The CSI Medical Index reflects the overall performance of listed companies in the medical and healthcare sector, including medical devices, services, and information technology [1] - The index has a base date of December 31, 2004, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the CSI Medical Index include WuXi AppTec (9.9%), Mindray Medical (9.27%), and Aier Eye Hospital (8.27%) [1] - The market share of the CSI Medical Index holdings is 57.98% from the Shenzhen Stock Exchange and 42.02% from the Shanghai Stock Exchange [1] - The industry composition of the CSI Medical Index holdings shows that 97.49% is in healthcare, 2.25% in information technology, and 0.26% in consumer goods [1] Group 3 - The index sample is adjusted every six months, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits are handled according to specific calculation and maintenance guidelines [2]

Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology industry [5]. Core Viewpoints - The report highlights the increasing external uncertainties following the US-China tariff conflict and expresses optimism towards domestic circulation and safe-haven assets in the pharmaceutical sector [2][20]. - The demand for blood products is relatively inelastic, and the recent tariff increases may lead to a short-term rise in imported albumin prices, benefiting domestic companies. The blood products industry is characterized by rigid demand and strategic resource attributes, suggesting a favorable competitive landscape for domestic alternatives [21]. - The report emphasizes the shift from "efficiency-first" to "safety-first" in supply chains, driven by the need for supply chain security, which may catalyze domestic replacements in high-end medical devices and scientific instruments [22][24]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index rose by 1.20%, outperforming the CSI 300 index by 2.57 percentage points and the ChiNext index by 3.55 percentage points, ranking third among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Medical Health Index increased by 1.32%, surpassing the Hang Seng Index by 3.49 percentage points [1][16]. Company Updates - Recent developments include the new listing application for SHR2554 tablets by Heng Rui Medicine and clinical application advancements for several products from Heng Rui Medicine and Lepu Biopharma [27]. Investment Strategy - The report suggests focusing on three main directions: policy support for hospital payments (innovative drugs and devices), expansion of public demand (blood products, home medical devices, weight loss drug supply chains), and an upward cycle for overseas payments (heparin, respiratory joint inspections) [24]. Key Company Profit Forecasts and Valuations - Key companies such as Mindray Medical, United Imaging, and Yuyue Medical are highlighted with projected earnings per share (EPS) and price-to-earnings (PE) ratios indicating a "Buy" recommendation [4]. Important Database Updates - The cumulative total number of hospital diagnoses showed a year-on-year increase of 13.29%, with significant growth in tertiary hospitals [30]. - The pharmaceutical manufacturing industry reported a year-on-year revenue decline of 3.4% for the first two months of 2025, with total revenue of 369.43 billion yuan [60].

Investment Rating - The report maintains an "Increase" rating for the medical device sector, indicating an expected investment return that exceeds the market benchmark index by 5% to 15% over the next 6-12 months [6]. Core Insights - The report highlights the potential acceleration of domestic high-end medical device replacement due to recent tariff changes, particularly in high-end medical imaging, surgical robots, and sequencing instruments [2][3]. - It emphasizes the importance of focusing on high-end innovative key areas supported by national policies, which are expected to facilitate faster commercialization of innovative medical devices [3]. - The report suggests that leading companies with strong R&D capabilities and brand recognition are likely to benefit from the ongoing trends in the industry [4]. Summary by Sections Industry Overview - The U.S. government announced a 34% tariff on all imports from the U.S. starting April 10, 2025, which is expected to impact the medical device sector significantly [1]. - The domestic medical imaging market currently has low industry concentration and small enterprise scale, with a low market share of domestic products in the mid-to-high-end segment [2]. Key Segments - High-end medical imaging equipment and core components are heavily reliant on imports, but domestic companies are making progress through technological innovation [2]. - The surgical robot market in China is dominated by imported products, particularly the Da Vinci surgical robot, but several domestic surgical robots have recently received approval for commercialization [2]. - The sequencing instrument market is significantly influenced by Illumina, Inc., which has been added to China's "unreliable entity list," potentially boosting domestic alternatives [2]. Policy Support - Recent initiatives from the National Medical Products Administration aim to optimize the regulatory framework for high-end medical devices, supporting innovation in key areas such as medical robots and AI medical devices [3]. - The report anticipates that strong R&D capabilities and leading product scales will benefit companies as they expand internationally [3]. Investment Recommendations - The report recommends increasing exposure to the medical device sector, particularly in high-end imaging equipment, surgical robots, sequencing instruments, and electrophysiology [4]. - Specific companies to watch include BGI Genomics, United Imaging, Mindray Medical, and others with strong R&D and market presence [4].

Industry Overview - The Chinese medical device industry is expected to exceed 1.2 trillion yuan in market size in 2024, representing a year-on-year growth of approximately 2.2% [1] - The demand for home medical devices is increasing due to factors such as accelerated population aging and heightened health management awareness among various demographics [1] - The home medical device market reached 234.3 billion yuan in 2023, with a year-on-year growth of 12.32%, indicating significant market potential [1] Company Profile - Yuyue Medical, established in 1998, focuses on the home medical device sector, covering various categories such as blood pressure monitoring, temperature monitoring, and respiratory care [2] - The company has transitioned from hospital-grade equipment to home-use products, leveraging advancements in IoT, big data, and AI to enhance product offerings and user experience [2] Product Innovation - Yuyue Medical has launched numerous innovative products, including the third-generation sleep apnea machine, which features personalized treatment plans and smart temperature control [3] - The company emphasizes user experience by developing a smart health service system that includes IVR voice robots and a unified ticketing platform to better analyze user needs [3] Research and Development - Yuyue Medical has established multiple research and innovation platforms, including a national enterprise technology center and 12 R&D centers globally, to enhance its technological capabilities [4] - The company has accumulated 1,495 authorized patents as of the end of 2023, reflecting its commitment to innovation in the home medical device sector [4] - Yuyue Medical aims to participate in international competition and accelerate its global strategy through technological innovation [4]